GlycoMimetics (GLYC) Stock Forecast, Price Target & Predictions
GLYC Stock Forecast
GlycoMimetics stock forecast is as follows: a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.
GLYC Analyst Ratings
According to 2 Wall Street analysts, GlycoMimetics's rating consensus is 'Hold'. The analyst rating breakdown for GLYC stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 26, 2024 | Cowen & Co. | - | Hold | Downgrade |
| May 06, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
GlycoMimetics's last stock rating was published by Cowen & Co. on Jul 26, 2024. The company Downgrade its GLYC rating from "null" to "Hold".
GlycoMimetics Financial Forecast
GlycoMimetics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 21 | Dec 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $1.06M | $162.94K | $9.00M |
| Avg Forecast | - | - | - | - | - | - | - | $50.00K | $1.19M | $333.33K | $15.00M |
| High Forecast | - | - | - | - | - | - | - | $50.00K | $1.42M | $333.33K | $18.00M |
| Low Forecast | - | - | - | - | - | - | - | $50.00K | $949.90K | $333.33K | $12.00M |
| # Analysts | - | - | - | - | - | - | - | 10 | 20 | 10 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | 0.89% | 0.49% | 0.60% |
GlycoMimetics's average Quarter revenue forecast for Jun 23 based on 10 analysts is $50.00K, with a low forecast of $50.00K, and a high forecast of $50.00K. GLYC's average Quarter revenue forecast represents a -95.26% decrease compared to the company's last Quarter revenue of $1.06M (Mar 21).
GlycoMimetics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 21 | Dec 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 10 | 20 | 10 | 18 |
| EBITDA | - | - | - | - | - | - | - | $-8.93B | $-14.21M | $-15.49M | $-7.59M |
| Avg Forecast | - | - | - | - | - | - | - | $-30.00K | $-15.98M | $-200.00K | $-10.63M |
| High Forecast | - | - | - | - | - | - | - | $-30.00K | $-12.79M | $-200.00K | $-8.51M |
| Low Forecast | - | - | - | - | - | - | - | $-30.00K | $-19.18M | $-200.00K | $-12.76M |
| Surprise % | - | - | - | - | - | - | - | 297664.83% | 0.89% | 77.47% | 0.71% |
undefined analysts predict GLYC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than GlycoMimetics's previous annual EBITDA (undefined) of $NaN.
GlycoMimetics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 21 | Dec 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 10 | 20 | 10 | 18 |
| Net Income | - | - | - | - | - | - | - | - | $-14.27M | $-15.56M | $-7.66M |
| Avg Forecast | $-22.57M | $-12.90M | $-12.90M | $-9.67M | $-5.16M | $-7.09M | $-10.80M | $-11.82M | $-16.06M | $-20.25M | $-10.73M |
| High Forecast | $-22.57M | $-12.90M | $-12.90M | $-9.67M | $-5.16M | $-6.00M | $-10.80M | $-11.82M | $-12.85M | $-20.25M | $-8.58M |
| Low Forecast | $-22.57M | $-12.90M | $-12.90M | $-9.67M | $-5.16M | $-9.28M | $-10.80M | $-11.82M | $-19.27M | $-20.25M | $-12.87M |
| Surprise % | - | - | - | - | - | - | - | - | 0.89% | 0.77% | 0.71% |
GlycoMimetics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GLYC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
GlycoMimetics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 21 | Dec 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 10 | 20 | 10 | 18 |
| SG&A | - | - | - | - | - | - | - | $4.86B | $4.19M | $4.01M | $4.44M |
| Avg Forecast | - | - | - | - | - | - | - | $21.78M | $517.26M | $145.21M | $6.22M |
| High Forecast | - | - | - | - | - | - | - | $21.78M | $620.71M | $145.21M | $7.46M |
| Low Forecast | - | - | - | - | - | - | - | $21.78M | $413.81M | $145.21M | $4.97M |
| Surprise % | - | - | - | - | - | - | - | 222.99% | 0.01% | 0.03% | 0.71% |
GlycoMimetics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to GLYC last annual SG&A of $4.86B (Jun 23).
GlycoMimetics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 23 | Mar 21 | Dec 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 10 | 20 | 10 | 18 |
| EPS | - | - | - | - | - | - | - | - | $-0.28 | $-0.32 | $-0.18 |
| Avg Forecast | $-0.35 | $-0.20 | $-0.20 | $-0.15 | $-0.08 | $-0.11 | $-0.17 | $-0.18 | $-0.31 | $-0.31 | $-0.30 |
| High Forecast | $-0.35 | $-0.20 | $-0.20 | $-0.15 | $-0.08 | $-0.09 | $-0.17 | $-0.18 | $-0.31 | $-0.31 | $-0.30 |
| Low Forecast | $-0.35 | $-0.20 | $-0.20 | $-0.15 | $-0.08 | $-0.14 | $-0.17 | $-0.18 | $-0.31 | $-0.31 | $-0.30 |
| Surprise % | - | - | - | - | - | - | - | - | 0.90% | 1.02% | 0.61% |
According to undefined Wall Street analysts, GlycoMimetics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GLYC previous annual EPS of $NaN (undefined).
GlycoMimetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GLYC | GlycoMimetics | $0.16 | $13.00 | 8025.00% | - |
| IVA | Inventiva | $2.42 | $36.00 | 1387.60% | Buy |
| ANTX | AN2 Therapeutics | $1.03 | $8.75 | 749.51% | Buy |
| SPRO | Spero Therapeutics | $1.29 | $10.00 | 675.19% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| CUE | Cue Biopharma | $1.11 | $5.00 | 350.45% | Buy |
| TRVI | Trevi Therapeutics | $3.12 | $9.00 | 188.46% | Buy |
| BCAB | BioAtla | $1.85 | $5.00 | 170.27% | Buy |
| MLYS | Mineralys Therapeutics | $13.88 | $30.00 | 116.14% | Buy |
| FHTX | Foghorn Therapeutics | $7.74 | $16.33 | 110.98% | Buy |
| ACHL | Achilles Therapeutics | $0.99 | $2.00 | 102.02% | Buy |
| TIL | Instil Bio | $39.46 | $78.25 | 98.30% | Hold |
| ASMB | Assembly Biosciences | $18.10 | $35.50 | 96.13% | Buy |
| DYN | Dyne Therapeutics | $34.73 | $43.88 | 26.35% | Buy |
GLYC Forecast FAQ
Is GlycoMimetics a good buy?
No, according to 2 Wall Street analysts, GlycoMimetics (GLYC) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of GLYC's total ratings.
What are GlycoMimetics's analysts' financial forecasts?
GlycoMimetics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-23.053M (high $-21.962M, low $-25.236M), average SG&A $0 (high $0, low $0), and average EPS is $-0.358 (high $-0.341, low $-0.391). GLYC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-58.035M (high $-58.035M, low $-58.035M), average SG&A $0 (high $0, low $0), and average EPS is $-0.9 (high $-0.9, low $-0.9).
Did the GLYC's actual financial results beat the analysts' financial forecasts?
Based on GlycoMimetics's last annual report (Dec 2020), the company's revenue was $10.16M, which missed the average analysts forecast of $15.33M by -33.72%. Apple's EBITDA was $-51.509M, beating the average prediction of $-10.832M by 375.52%. The company's net income was $-50.274M, beating the average estimation of $-30.976M by 62.30%. Apple's SG&A was $16.74M, missing the average forecast of $151.43M by -88.94%. Lastly, the company's EPS was $-1.1, beating the average prediction of $-0.61 by 80.33%. In terms of the last quarterly report (Mar 2021), GlycoMimetics's revenue was $1.06M, missing the average analysts' forecast of $1.19M by -11.11%. The company's EBITDA was $-14.206M, missing the average prediction of $-15.982M by -11.11%. GlycoMimetics's net income was $-14.274M, missing the average estimation of $-16.058M by -11.11%. The company's SG&A was $4.19M, missing the average forecast of $517.26M by -99.19%. Lastly, the company's EPS was $-0.28, missing the average prediction of $-0.31 by -9.68%